Nootropil 800mg: Advanced Cognitive Support for Neurological Health
| Product dosage: 800mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $1.11 | $66.66 (0%) | 🛒 Add to cart |
| 90 | $1.08 | $99.99 $96.96 (3%) | 🛒 Add to cart |
| 120 | $1.05 | $133.31 $126.25 (5%) | 🛒 Add to cart |
| 180 | $1.03 | $199.97 $185.83 (7%) | 🛒 Add to cart |
| 270 | $1.02 | $299.96 $275.72 (8%) | 🛒 Add to cart |
| 360 | $1.02
Best per pill | $399.94 $366.62 (8%) | 🛒 Add to cart |
Synonyms
| |||
Nootropil, with its active ingredient piracetam, represents a cornerstone of modern nootropic pharmacotherapy. As a member of the racetam class, it functions as a cyclic derivative of the neurotransmitter GABA, though its mechanism extends beyond mere GABAergic activity. This medication is primarily indicated for the management of cortical myoclonus and as adjunctive therapy for various cognitive disorders. Its neuroprotective and neuromodulatory properties make it a valuable tool in neurological and psychiatric practice, offering a favorable safety profile that has been demonstrated through decades of clinical use across numerous patient populations.
Features
- Contains piracetam as the active pharmaceutical ingredient (800mg per tablet)
- Exhibits high bioavailability with rapid absorption following oral administration
- Demonstrates excellent cerebrospinal fluid penetration and blood-brain barrier permeability
- Features minimal protein binding characteristics (<10%)
- Maintains linear pharmacokinetics across therapeutic dosing ranges
- Shows no significant hepatic metabolism, primarily excreted unchanged renally
- Available in multiple formulations including tablets, oral solution, and injectable forms
- Manufactured under strict pharmaceutical GMP compliance standards
Benefits
- Enhances neuronal membrane fluidity and facilitates interhemispheric communication
- Improves learning capacity and memory consolidation through cholinergic system modulation
- Reduces neuronal excitability and seizure activity through GABAergic mechanisms
- Supports cognitive recovery following cerebral ischemia or traumatic brain injury
- Demonstrates neuroprotective effects against various neurotoxic insults
- Improves rheological properties of blood, enhancing cerebral microcirculation
Common use
Nootropil is primarily prescribed for the management of cortical myoclonus, either as monotherapy or in combination with other anticonvulsants. It finds significant application in cognitive disorders including post-stroke cognitive impairment, dementia syndromes (particularly vascular dementia and Alzheimer’s disease), and age-related cognitive decline. The medication is also utilized off-label for various neurological conditions including vertigo of central origin, dyslexia, and sickle cell anemia. In psychiatric practice, it may be adjunctively used for cognitive deficits associated with schizophrenia and other psychotic disorders. The therapeutic application extends to rehabilitation settings for patients recovering from traumatic brain injury or cerebral hypoxia.
Dosage and direction
For cortical myoclonus management, initial dosing typically begins at 7.2g daily, divided into two or three doses, with gradual titration upward by 4.8g daily every three to four days until optimal response is achieved. Maximum recommended dosage is 24g daily. For cognitive disorders, dosing generally ranges from 2.4g to 4.8g daily in divided doses. Administration should occur with meals to minimize potential gastrointestinal discomfort. Tablet formulation should be swallowed whole with adequate fluid intake. Dosage adjustment is necessary in patients with renal impairment, with creatinine clearance below 60 mL/min requiring proportional reduction. Treatment duration varies by indication but often extends for several months with regular clinical reassessment.
Precautions
Renal function should be assessed prior to initiation and monitored periodically during treatment, particularly in elderly patients. Dose reduction is mandatory in renal impairment. Caution is advised in patients with bleeding disorders or those taking anticoagulant therapy due to potential effects on platelet aggregation. Patients with history of major psychiatric disorders should be monitored for potential exacerbation of symptoms. Discontinuation should be gradual rather than abrupt, particularly in epilepsy patients, to avoid withdrawal phenomena. Use during surgical procedures requires consideration of its effects on hemostasis. Regular hematological and biochemical monitoring is recommended during prolonged therapy.
Contraindications
Nootropil is contraindicated in patients with known hypersensitivity to piracetam or any excipients in the formulation. It must not be used in patients with severe renal impairment (creatinine clearance <20 mL/min) or end-stage renal disease requiring dialysis. The medication is contraindicated in patients with cerebral hemorrhage or active intracranial bleeding. It should not be administered to patients with Huntington’s chorea due to potential exacerbation of symptoms. Use is prohibited in patients with history of severe hepatic impairment. Pregnancy and lactation represent absolute contraindications unless potential benefit outweighs risk under specialist supervision.
Possible side effect
Common adverse reactions include nervousness (7-12%), weight gain (5-8%), and somnolence (4-6%). Gastrointestinal effects such as nausea (3-5%), abdominal pain (2-4%), and diarrhea (2-3%) may occur. Neurological side effects can include dizziness (4-7%), headache (3-5%), and insomnia (2-4%). Psychiatric manifestations might involve agitation, anxiety, or depression in susceptible individuals (1-3%). Rare but serious side effects include severe dermatological reactions, thrombophlebitis (particularly with intravenous administration), and exacerbation of pre-existing movement disorders. Most adverse effects are dose-dependent and reversible upon dosage adjustment or discontinuation.
Drug interaction
Nootropil may potentiate the effects of anticoagulants such as warfarin, requiring closer monitoring of coagulation parameters. Concomitant use with other CNS depressants including benzodiazepines, barbiturates, or alcohol may enhance sedative effects. It may interact with thyroid hormone replacement therapy, potentially necessitating dosage adjustment. Co-administration with antihypertensive agents might require blood pressure monitoring. The medication shows minimal interaction with cytochrome P450 enzyme system but may affect drugs renally excreted through competition for tubular secretion. Concurrent use with other nootropic agents or psychostimulants should be carefully monitored for synergistic effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In such case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling of doses to compensate for missed administration is not recommended. For patients on multiple daily dosing, if remembered within 4 hours of the missed time, the dose may be taken. Beyond this window, waiting until the next scheduled dose is preferable. Maintenance of consistent blood levels is important for therapeutic efficacy, particularly in seizure management.
Overdose
Symptoms of overdose may include severe diarrhea, abdominal pain, and pronounced sedation. In extreme cases, neurological symptoms including confusion, agitation, or exacerbation of seizure activity may occur. Management is primarily supportive with gastric lavage considered if presentation occurs within one hour of ingestion. Activated charcoal administration may be beneficial. Hemodialysis is effective for removal due to low protein binding and predominantly renal excretion. Symptomatic treatment should address specific manifestations with close monitoring of vital signs and neurological status. There is no specific antidote available.
Storage
Store at controlled room temperature between 15-30°C (59-86°F). Protect from moisture and direct sunlight. Keep container tightly closed when not in use. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. For oral solution, once reconstituted, store in refrigerator and use within the specified timeframe (typically 4-6 weeks). Tablets should be kept in original packaging until use to maintain stability.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient response may vary based on numerous factors including age, renal function, concomitant medications, and underlying medical conditions. Prescription and use of Nootropil should only occur under supervision of a qualified healthcare professional familiar with the patient’s complete medical history. Dosage adjustments and treatment decisions must be made by appropriate medical personnel. Always consult with a healthcare provider before starting, stopping, or changing any medication regimen.
Reviews
Clinical studies demonstrate significant efficacy in cortical myoclonus management with response rates exceeding 60% in refractory cases. Meta-analyses of cognitive disorders show modest but statistically significant improvement in memory performance and global cognitive function scores. Long-term observational studies indicate good tolerability profile with sustained therapeutic benefit over extended treatment periods. Patient-reported outcomes generally reflect improvements in quality of life measures, particularly in activities of daily living and social functioning. Specialist neurologists consistently rate Nootropil as valuable adjunctive therapy within comprehensive treatment approaches for various neurological conditions.